Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Michael Nedelcovych

Michael Nedelcovych

Analyst, TD Cowen

Appears in 1 story

Notable Quotes

"These data outstrip Sotyktu and look as good or better than oral IL‑23s like icotrokinra." — Michael Nedelcovych, TD Cowen via Reuters

Stories

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

New Capabilities

Positive on data; cautious on overall oral psoriasis market sizing

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated Yesterday